NASDAQ · UTHR
Healthcare · Biotechnology
$515.46
Down-$12.45 (-2.36%)
Updated Aug 31, 2026, 11:45 AM
SID Score
6.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
UTHR closed at $515.46 after 20 trading sessions, down 0.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $527.94 | $530.50 | $513.72 | $515.46 | 266.87K |
| Aug 27, 2026 | $513.98 | $531.76 | $511.00 | $527.91 | 391.01K |
| Aug 26, 2026 | $515.60 | $522.0199 | $513.98 | $516.68 | 254.78K |
| Aug 25, 2026 | $516.07 | $520.655 | $515.54 | $518.53 | 876.5K |
| Aug 24, 2026 | $513.12 | $514.295 | $508.1541 | $512.88 | 323.89K |
| Aug 21, 2026 | $523.23 | $528.02 | $512.29 | $513.12 | 415.57K |
| Aug 20, 2026 | $524.15 | $529.255 | $517.88 | $521.00 | 440.39K |
| Aug 19, 2026 | $525.47 | $535.77 | $522.04 | $529.14 | 432.11K |
| Aug 18, 2026 | $510.42 | $519.21 | $508.56 | $518.27 | 366.43K |
| Aug 17, 2026 | $502.29 | $509.54 | $499.96 | $508.48 | 457.34K |
| Aug 14, 2026 | $498.91 | $501.62 | $494.345 | $499.73 | 472.96K |
| Aug 13, 2026 | $515.62 | $515.62 | $499.19 | $501.27 | 408.06K |
| Aug 12, 2026 | $510.44 | $521.4299 | $506.01 | $511.72 | 326.13K |
| Aug 11, 2026 | $528.06 | $534.41 | $512.47 | $515.50 | 343.39K |
| Aug 10, 2026 | $528.595 | $540.5625 | $523.37 | $529.66 | 642.77K |
| Aug 7, 2026 | $534.84 | $541.03 | $524.58 | $538.84 | 1.2M |
| Aug 6, 2026 | $519.79 | $533.12 | $511.99 | $532.94 | 998.78K |
| Aug 5, 2026 | $505.00 | $525.78 | $490.80 | $519.01 | 742.76K |
| Aug 4, 2026 | $517.86 | $521.18 | $511.93 | $518.68 | 522.27K |
| Aug 3, 2026 | $516.29 | $519.7399 | $514.01 | $516.31 | 427.63K |
The latest Smart Investors Daily articles mentioning UTHR.
UTHR research
Company profile and research snapshot.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Jul 23, 2026 | JP Morgan | Overweight | — |
| Jul 10, 2026 | B of A Securities | Neutral | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
| May 7, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients
Yahoo · Aug 21, 2026
MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ahead of Keytruda's 2028 LOE.
ChartMill · Aug 20, 2026
United Therapeutics passes the Caviar Cruise quality screen with 14% revenue growth, 28% ROIC, and zero debt—making it a standout quality investment.
Yahoo · Aug 19, 2026
Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning UTHR.
